Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225040 · ClinicalTrials.gov registry record
Bone MicroArchitecture in Acromegaly
A clinical trial of Acromegaly and Osteoporosis Risk, sponsored by Columbia University.
- Completed
- Registry status
- 77
- Enrollment target
- 1
- Study location
NCT03225040: Completed study of Acromegaly and Osteoporosis Risk, sponsored by Columbia University.
NCT03225040 is a study of Acromegaly and Osteoporosis Risk that has completed, run by Columbia University. The registered enrollment target is 77 participants, below the 95-participant average among 13 other Acromegaly trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03225040, a study of Acromegaly and Osteoporosis Risk, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to describe the bone architecture and associated biochemical indices of bone turnover and metabolism in patients with active acromegaly and how these are altered with treatment of the disease.
Primary Outcome
Volumetric bone mineral density of radius (vBMD) measured by high resolution peripheral quantitative computed tomography (HRpQCT)
Conditions Studied
Interventions
- DRUG Pegvisomant
Study Locations (1)
New York
- Neuroendocrine Unit and Pituitary Center, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-08-03 |
| Est. Completion | 2019-12-21 |
What the finished NCT03225040 record still lists
NCT03225040 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 95-participant average among 13 other Acromegaly trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Acromegaly appearing as the primary indexed condition, and to 1 intervention - of which Pegvisomant is the first listed.
NCT03225040 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03225040 about?
NCT03225040 is a clinical study titled "Bone MicroArchitecture in Acromegaly". The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth f...
What is the current status of trial NCT03225040?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2016-08-03. Estimated completion is 2019-12-21.
What conditions does trial NCT03225040 study?
This clinical trial studies the following conditions: Acromegaly, Osteoporosis Risk.
What interventions are being tested in trial NCT03225040?
The interventions under investigation include: Pegvisomant (DRUG).
Who is sponsoring clinical trial NCT03225040?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03225040 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03225040's enrollment target sits among peer trials
77 5th of 13 higher than 9 of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI